These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35863944)

  • 21. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
    Yuan L; Rahman M; Concato J
    Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
    Hiramatsu K; Barrett A; Miyata Y;
    Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust.
    Oehrlein EM; Graff JS; Harris J; Perfetto EM
    Patient; 2019 Aug; 12(4):375-381. PubMed ID: 30666526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms.
    Beyrer J; Abedtash H; Hornbuckle K; Murray JF
    J Comp Eff Res; 2022 May; 11(7):499-511. PubMed ID: 35296149
    [No Abstract]   [Full Text] [Related]  

  • 25. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
    Mullins CD; Sanchez RJ
    J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.
    Facey KM; Rannanheimo P; Batchelor L; Borchardt M; de Cock J
    Int J Technol Assess Health Care; 2020 Sep; ():1-10. PubMed ID: 32878663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Data Science Methods for Real-World Evidence Generation in Real-World Data.
    Liu F
    Annu Rev Biomed Data Sci; 2024 Aug; 7(1):201-224. PubMed ID: 38748863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transferability of real-world data across borders for regulatory and health technology assessment decision-making.
    Jaksa A; Arena PJ; Chan KKW; Ben-Joseph RH; Jónsson P; Campbell UB
    Front Med (Lausanne); 2022; 9():1073678. PubMed ID: 36465931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.
    Facile R; Muhlbradt EE; Gong M; Li Q; Popat V; Pétavy F; Cornet R; Ruan Y; Koide D; Saito TI; Hume S; Rockhold F; Bao W; Dubman S; Jauregui Wurst B
    JMIR Med Inform; 2022 Jan; 10(1):e30363. PubMed ID: 35084343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.
    Zhu R; Vora B; Menon S; Younis I; Dwivedi G; Meng Z; Datta-Mannan A; Manchandani P; Nayak S; Tammara BK; Garhyan P; Iqbal S; Dagenais S; Chanu P; Mukherjee A; Ghobadi C;
    Clin Pharmacol Ther; 2023 Oct; 114(4):751-767. PubMed ID: 37393555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases.
    Timbie JW; Kim AY; Baker L; Li R; W Concannon T
    J Comp Eff Res; 2024 Sep; 13(9):e240078. PubMed ID: 39150225
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of Real-World Evidence for Drug Regulatory Decisions in China: Current Status and Future Directions.
    Li P; Wang S; Chen Y
    Ther Innov Regul Sci; 2023 Nov; 57(6):1167-1179. PubMed ID: 37624556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
    Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
    Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
    Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
    Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
    Thompson D
    Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Practical considerations of utilizing propensity score methods in clinical development using real-world and historical data.
    Li Q; Lin J; Chi A; Davies S
    Contemp Clin Trials; 2020 Oct; 97():106123. PubMed ID: 32853779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward.
    Akehurst R; Murphy LA; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):11-19. PubMed ID: 36706952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    J Cancer Policy; 2023 Jun; 36():100424. PubMed ID: 37116794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.